Case report of a brain abscess due to Nannizziopsis obscura species complex in a renal transplanted patient Authors: Othman Mounir Alaoui, Astrid De Liège, Frédéric Mechai, Dea Garcia-Hermoso, Fanny Lanternier, Bertrand Degos Published: 2026 ABSTRACT AbstractWe here describe the case of a kidney transplant patient from Mali who presented with multiple complex seizures followed by a facial paresis revealing a brain abscess due to Nannizziopsis obscura species complex. This fungal species is usually implicated in reptile skin infections and rarely disseminated infections. Very rarely, it can infect human beings suffering from immunodepression, causing various kinds of complications ranging from soft tissue abscesses to solid organ abscesses. This case highlights the potential wide range of pathogens involved and underlines the need for greater vigilance in the diagnosis and management of atypical infections in transplant settings.Keywords: Nannizziopsis, Brain abscess, Immunosupression, Fungal infection Abbreviation: cytomegalovirus cerebrospinal fluid Ebstein-Barr virus Hepatitis B virus human immunodeficiency viruses Human Herpesvirus Herpes simplex virus magnetic resonance imagery Nanniziopsis polymerase chain reaction species plurimae Introduction Brain abscesses are a rare but serious complication of solid organ transplantation due to the drug-induced immunosuppression required to prevent transplant rejection. It is estimated to occur in less than 1% of transplant patients, with high mortality rates [1], [2], [3]. Identification of the causative pathogen is crucial to provide the right treatment and improve outcomes. However, this process can be quite difficult because the clinical symptoms and paraclinical examinations may not be very specific [4], [5]. Nannizziopsis spp. is an emerging infectious pathogen affecting reptiles and amphibians with a tropism for keratin, causing skin infections that sometimes extend to several organs [6]. It is exceptionally associated with human infections and only a few cases have been reported (see Table 1). Here, we describe the case of a brain abscess caused by N. obscura in a patient who had undergone a kidney transplant. Table 1Characteristics of all reported cases of Nannizziopsis infections.Table 1DateGenderAgeContext and risk factorsOriginAffected organDiagnosisIsolated speciesTreatmentFollow-up1982 [7], [8]Male24UnknownTrips to AfricaAbscess on right ankle + osteomyelitisAbscess biopsyN. obscuraAmphotericin BCured at M4, persistent lytic area on X-ray at Y21994 [8]MaleN/AHIV+N/AMass in right thigh, lungsMuscle biopsyN. hominisItraconazoleDeath after 8 months probably from HIV complications2000 [8]Male32ImmunocompetentTrips to NigeriaLymph nodes, heart, lungs, spleen, kidneysLymph nodes biopsyN. hominisItraconazole for 2 yearsUnknown2004 [9]Male49HIV+0 CD4MaliLiver abscessNeedle aspiration of the liverN. obscuraAmphotericin B + Metronidazole at least 15 daysNo follow-up2005 [10]Male38HIV+; 102 CD4NigeriaBrain abscessNeedle aspiration of brain lesionChrysosporium anamorph of N. vriesiiVoriconazole + aspirationAt M4: in good health with no neurological deficit, partial regression of brain lesions2005 [11], [12]Male40HIV+; 13 CD4UnknownLungsBronchial washingChrysosporium anamorph of N. vriesiiNo treatmentNo follow-up2009 [9]Male50Heart transplantation (2009)Prednisone 15mg + CiclosporinMaliMultiple organ damageBlood cultureN. obscuraNo treatmentDeath before treatment2015 [12]Female63T-cell prolymphotic leukemia (2014) treated with Alemtuzumab then Bendamustine then IdelalisibSeveral trips to SenegalBrain abscessBlood culture, CSF, ascites fluidN. obscuraDeath before antifungal treatmentDeath before antifungal treatment2015 [13]Male34Kidney transplantationTacrolimus, MMF, Prednisone 5mgGambiaChronic subcarinal lymphadenopathy (2 months), pulmonary nodules, soft tissue collection in T6-T8 then collection of thoracic musculatureSurgical drainage of the thoracic muscle collection + lymph node biopsyN. obscuraSurgical drainage + Posaconazole for 10 monthsImprovement of thoracic collection and skin lesions at M3, no evidence of recurrence at M172017 [9]Female58Kidney transplantation (2016)Tacrolimus, MMF, Prednisone 5mgMaliLung nodule + nodular skin lesions on both legsSkin and lung biopsyN. obscuraVoriconazole then Posaconazole for 8 months + reduction of Tacrolimus and switch MMF for AzathioprineResidual hypermetabolic lesion at M6, end of treatment at M8, no relapse at Y12017 [9]Male62Kidney transplantation (2009)Tacrolimus, MMF, Prednisone 5mgGuineaSuppurated lesions on the right fibulaDirect examination of infected lesionsN. obscuraVoriconazole then posaconazole for 2 yearsResidual hypermetabolism of the right ankle at M6, no hypermetabolism at Y22017 [12]Female52HIV+; 3 CD4MaliBrain abscess + nodular lesion of the right lungCerebral biopsy, CSFClosely related to N. obscuraFluconazole + Pyrimethamine-Sulfadiazine then Amphotericin then VoriconazoleM1: improvement of general status, regression of lung lesions and cerebral abscess2018 [9]Female69Advanced mantle cell lymphoma treated in 2017T-cell lymphoma discovered during hospitalizationGuineaLung lesions + lymphadenopathy + nodular hyperchromic skin lesionsSkin biopsiesN. obscuraVoriconazole + Amphotericin B then diedDeath despite intensive care and antifungal treatment2018 [9]Female27No notable medical historyGuineaMediastinal massSurgical resectionN. obscuraPosaconazole then Voriconazole duration unknownReduction in mass size at M72018 [9]Male38Kidney transplantation (2015)Tacrolimus, MMF, Prednisone 5mgMaliBrain abscessCerebral biopsyN. obscuraAmphotericin B + Fluconazole then Amphotericin B + voriconazoleStill alive at M122019 [9]Male79Kidney transplantation (2014)Tacrolimus, MMF, Prednisone 5mgMaliUlcerative lesion of the fifth right finger + pulmonary noduleSkin biopsyN. obscuraItraconazoleImprovement at M42019 [9]Male65Kidney transplantation (2018)Tacrolimus, MMF, Prednisone 5mgMaliLeft clavicle abscessCulture of pus from spontaneous fistulaN. obscuraVoriconazoleUnknown2019 [14]Male56Kidney transplantation (2013)Tacrolimus, MMF, Prednisone 5mgSenegalAnkle arthritisDebridement of skin and subcutaneous tissue, histological examination + culture of pusN. obscuraSurgery + Amphotericin B for 5 days then Voriconazole (ultra-rapid metabolizer profile) then Posaconazole for 1 yearNo recurrence + partially functional right lower limb at Y12020 [15]Female13STAT1 mutationNigeriaBrain abscess + osteomyelitis + pneumoniaBone biopsy + cerebral biopsyNanniziopsis spp.Ventricular drain + Amphotericin B then VoriconazoleAlmost complete resolution of brain lesions at M4, removal of ventricular drain at M112021 [16]Male35HIV+; 4 CD4TogoBrain abscess + cavitary lesion of the right upper lungBronchial washingNanniziopsis spp.Voriconazole 12 weeksReduction in lesion size at M3, asymptomatic at M182021 [17]Female45Kidney transplantationPrednisone 5 mg, Tacrolimus 9 mg - 8,5 mg, MMF 500 mg - 250 mgNigeriaBreast abscessNeedle biopsyN. obscuraDrainage + Anidulafungin 100 mg IV 14 days + reducing the Tacrolimus dose to reach a target level of 4–5 ng/mL switch to Isavuconazole 600 mg for two days and a subsequent dose of 200 mg daily for a total of 14 more daysUnknown2022Male54Kidney transplantationSirolimus 1.5mg Tacrolimus 7mg Prednisone 5mgMaliBrain abscessBrain biopsyN. obscuraAmphotericin B + Flucytosin then VoriconazoleClinically asymptomatic and partial regression of the brain lesion at M82023 [18]N/AN/AN/AVenezuelaTongue lesionBiopsy ?N. arthrosporioidesN/AN/AAbbreviations. CSF: cerebrospinal fluid; HIV: human immunodeficiency viruses; M: month; MMF: mofetil mycophenolate; N: Nannizziopsis; N/A: not available; Spp: species plurimae; Y: year. Characteristics of all reported cases of Nannizziopsis infections. Abbreviations. CSF: cerebrospinal fluid; HIV: human immunodeficiency viruses; M: month; MMF: mofetil mycophenolate; N: Nannizziopsis; N/A: not available; Spp: species plurimae; Y: year. Case presentation In July 2022, a 54-year-old patient from Mali presented with multiple complex motor seizures followed by post-ictal right hemiplegia. The patient had a history of renal transplantation in 2017 after 4 years of dialysis due to nephroangiosclerosis. He suffered from multiple infectious complications due to his immunosuppression: pulmonary and lymphatic infection due to Mycobacterium intracellulare, CMV and HBV reactivation, and Kaposi disease with pulmonary, lymphatic and cutaneous localizations, all of which were considered as resolved before the onset of symptoms. In particular, to treat Kaposi disease, dermatologists decided to reduce immunosuppression by replacing mycophenolate mofetil with sirolimus in September 2019, but still in combination with tacrolimus and prednisone, resulting in a significant improvement seen after 3 months and persisting thereafter. On admission (Day 0), he was receiving immunosuppressive drugs (sirolimus 1.5mg, tacrolimus 7mg and prednisone 5mg, daily). Initial management in the intensive care unit consisted of administering anti-epileptic drugs and undertaking diagnostic investigations. He was apyretic and had no new neurological symptoms on admission. Blood tests on admission showed no abnormalities, except for a known increase in creatinine level around 220 μmol/L (normal level < 115 μmol/L). A magnetic resonance imaging (MRI) displayed a discrete left frontal lesion with contrast enhancement on T1-weighted sequences, without diagnostic orientation (Fig. 1a and b). Brain Imagery and anatomopathological examination of the brain lesion a: Day 1, T2 FLAIR-weighted brain MRI showing a heterogenous left frontal cortico-subcortical hyperintensity (white arrow). b: Day 1, Gadolinium-injected T1-weighted brain MRI showing a contrast enhancement in the same region (white arrow). c: Day 18 (1 day after neurological worsening), T2 FLAIR-weighted brain MRI showing a large increase in lesion size with peri-lesional oedema. d: Day 18 (1 day after neurological worsening), Gadolinium-injected T1-weighted brain MRI showing increased contrast enhancement associated with a heterogeneous appearance. e: M8, T2-weighted FLAIR brain MRI showing a significant decrease in lesion size. f: M8, Gadolinium-injected T1-weighted brain MRI showing the disappearance of the contrast enhancement. g: Grocott–Gömöri's methenamine silver stain (black) of the brain biopsy demonstrating the presence of fungal elements. Cerebrospinal fluid (CSF) analyses performed on day + 1 showed no pleocytosis nor hypoglycorrhachia. Polymerase chain reaction (PCR) for CMV, EBV, HSV1, HSV2, JC, HHV6, HHV8, enterovirus, Toxoplasma gondii, Nocardia, Mycobacterium tuberculosis was negative, as were bacterial cultures, Aspergillus (galactomannan) antigen and India ink stain for Cryptococcus. On day + 5, the patient was transferred in our Neurology department at Avicenne University hospital for further examination. A thoraco-abdomino-pelvic computed tomography scan was performed on day + 6 and revealed a newly developed nodule in the lower lobe of the left lung, which had not previously been seen in January 2022, at the time of the last systematic evaluation after Kaposi disease. A bronchial fibroscopy performed on day + 7 revealed no signs of malignancy, and bacterial and mycobacterial cultures of bronchoalveolar lavage fluid were all negative. On day + 17, the patient presented a right central facial paralysis. MRI performed after this neurological worsening on day + 18 showed a significant increase in the size and contrast of the initial lesion (Fig. 1c and d), leading us to suspect an infectious disease as a first hypothesis. We especially suspected parasitic infections such as bilharzia, given the radiological characteristics of the lesion showing an ill-defined tumor-like enhancement and the presence of bladder calcifications. A second CSF analysis performed at day + 19 was normal. Control PCR for CMV, EBV, HSV1, HSV2, JC, HHV6, HHV8 and Mycobacterium tuberculosis were negative. Bacterial cultures were taken on day + 19 and were also negative. Immunophenotyping and interleukin assays revealed no evidence for neurolymphoma. Stool, urine and blood analyses performed on day + 19 were also negative for parasitologic and mycological tests. Given the negativity of all blood and cerebral fluid tests, a neurosurgical biopsy was performed on day + 27 to identify the pathogen. Histopathological examination of the brain biopsy showed numerous non-necrotizing epithelioid and multinucleated giant cell granulomas, associated with a mixed inflammatory infiltrate. Fungal elements were observed within the lesion (Fig. 1G). We therefore began treating the patient with amphotericin B 3mg/kg/24h and flucytosine 25mg/kg/12h on day + 28. Fungal cultures resulted in the growth of yeasts and filamentous elements. However, morphological features were non-specific and did not allow species-level identification. MALDI-TOF mass spectrometry suggested identification within the genus Nannizziopsis. Species-level identification was achieved by molecular analysis as described in Garcia-Hermoso et al. [9]. Sequences of the internal transcribed spacer (ITS) region and of the actin gene were compared against curated fungal references databases using BLAST (https://blast.ncbi.nlm.nih.gov) allowing the identification of the species obscura. In accordance with the literature, the patient was then treated with intravenous voriconazole at a loading dose of 6mg/kg/12h, followed by a maintenance dose of 4mg/kg/12h (220 mg/12h). Therapeutic drug monitoring revealed an insufficient initial serum level at 2.65 mg/L, prompting a dose adjustment to 4.5 mg/kg/12h (250 mg/12h). In vitro antifungal susceptibility testing of the isolate demonstrated minimum inhibitory concentrations of 0.5 mg/L for amphotericin B, 0.125 mg/L for itraconazole, 0.25 mg/L for voriconazole, 0.03 mg/L for posaconazole, 0.25 mg/L for isavuconazole, 1 mg/L for caspofungin and < 0.008 mg/L for micafungin. Subsequent monitoring showed a stable concentration of voriconazole within the target range between 3.5 and 5 mg/L. After a two weeks course of intravenous therapy, the patient was transitioned to oral voriconazole at a dose of 250 mg/12h prior to discharge, resulting in favorable clinical and radiological outcomes. At the 8-month follow-up (M8), the patient was still under voriconazole 4mg/kg/12h. He was neurologically asymptomatic and brain MRI showed an improvement in the evolution of the lesions (Fig. 1e and f). Patient was then lost to follow-up. Discussion Brain abscesses are a rare but serious complication of solid organ transplantation. The most common clinical presentations are fever and altered mental status. Patients may also present with focal neurological symptoms or epileptic seizures, as in the case of our patient [4]. The epidemiology of brain abscesses in transplant patients seems to depend on the onset of infection in relation to the moment of transplantation: early-onset brain abscesses (less than 6 months after transplantation) are mainly due to fungal infections and late brain abscesses may be caused by other pathogens (Nocardia, Toxoplasma gondii) [1]. Fungal infections of the brain are difficult to diagnose because clinical symptoms and brain imaging are not very specific. CSF analysis can be very useful for assessing the presence of fungal antigens (galactomannan, β-D-Glucan) but definitive identification of the pathogen is often difficult. The search for other infected organs (lymph nodes, lungs, skin) with potential biopsy sites can help make the right diagnosis [5]. However, when first- and second-line investigations are negative, specialist discussions between neurologists, infectious disease specialists and neurosurgeons are needed to determine the indication for a brain biopsy. In our case, only a brain biopsy was able to identify the pathogen responsible for the brain abscess. Nannizziopsis spp. are keratinophylic fungi first described from day geckos (Phelsuma sp.) in 1991. They have subsequently been described in several different reptile species. They mainly cause skin infections that can spread and lead to the failure of several organs [6]. Very rarely, these fungi can infect humans, leading to various localizations of infection, such as the lung, kidney, liver, spleen, brain, breast, lymph nodes, soft tissues, bones and articulations. To our knowledge, only 22 other cases of human Nannizziopsis infections have been described in the literature (Table 1), our patient being the second kidney transplant patient with a brain abscess due to N. obscura. The main risk factor appears to be immunosuppression, as only one reported case (5%) involved an immunocompetent patient at the onset of symptoms. All reported conditions (i.e. HIV infection, solid organ transplantation, T-cell lymphoma, STAT1 mutation) result predominantly in T-cells deficiencies rather than other kinds of immunodeficiency. In addition, almost all patients originate from, or have traveled to, West African countries. However, several years may elapse between the last trip in one of these countries and the onset of symptoms. Only one case has been reported in Venezuela, but no clinical data on other risk factors are available. As for our patient, his last trip to Mali was more than 4 years before his first symptoms. This raises the question whether patients carry a latent form of this fungus that reactivates upon immunosuppression. Diagnosis consistently relies on invasive sampling of the affected organs, including stereotactic brain biopsies, bone and skin biopsies, or deep aspiration cultures. Nannizziopsis obscura is the most frequently identified species, followed by N. hominis and N. vriesii. Macroscopically, Nannizziopsis isolates produce moderately fast-growing, yellowish, velvety to powdery colonies on PDA [7,9]. Under microscopy, they commonly exhibit sessile aleurioconidia with truncate bases. They typically have chains of cylindrical arthroconidia formed by schizolytic hyphal fragmentation; and short undulate lateral branches. However, these phenotypic traits overlap considerably across the genus, rendering DNA sequencing essential for definitive species identification. Antifungal management is heterogenous but centers predominantly on broad-spectrum azoles and amphotericin B formulations, frequently combined with surgical drainage or reduction of immunosuppressive therapy. Given the invasive nature and slow resolution of deep-seated and central nervous system lesions, prolonged antifungal courses are required, ranging from several months to over two years. When diagnosed early and with prolonged azole treatment, favorable clinical and radiological outcomes can be achieved. However, the prognosis remains guarded, with notable mortality especially in case of delayed antifungal therapy. In conclusion, Nannizziopsis spp. Should be considered an emerging opportunistic pathogen in patients with marked cell-mediated immunosuppression with epidemiological links to West Africa, in whom early tissue-based diagnosis and extended triazole therapy are critical to improving clinical outcomes. CRediT authorship contribution statement Othman Mounir Alaoui: Writing – original draft, Visualization, Investigation, Conceptualization. Astrid De Liège: Writing – review & editing, Investigation. Frédéric Mechai: Investigation. Dea Garcia-Hermoso: Writing – review & editing, Resources, Methodology. Fanny Lanternier: Resources, Methodology. Bertrand Degos: Writing – review & editing, Supervision, Conceptualization. Consent to publish: The authors affirm that the patient provided informed consent for publication of this case and of Fig. 1. Data availability statement The data are not available for public access because of patient privacy concerns but are available from the corresponding author BD on reasonable request. Consent In accordance with French law, the patient was informed, via an information sheet, that his medical records might be used for research purposes, and all data that could potentially identify him were pseudonymised during the data extraction process in order to protect his confidentiality. Written informed consent was not required for this retrospective case study. Funding source There are none. Conflict of interest There are none. Acknowledgements The authors thank the neurosurgery department of the Beaujon Hospital (Pr. Stéphane Goutagny), Dr. Marie MONGIN, the parasitology departments of the Avicenne Hospital and Bichat Hospital (Dr. Sophie Brun, Dr. Anthony Marteau, Dr. Christine Bonnal) and the France's National Reference Center for Invasive Mycoses and Antifungals for their help in identifying the causative pathogen of our patient's abscess (Dea Garcia-Hermoso and Françoise Dromer). References Associated Data Data Availability Statement The data are not available for public access because of patient privacy concerns but are available from the corresponding author BD on reasonable request.